Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 15/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 15/20 | 0.66 |
| ▸ | RECQL | P46063 | 14/20 | 0.66 |
| ▸ | MAPT | P10636 | 13/20 | 0.66 |
| ▸ | APEX1 | P27695 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALPL | P05186 | 1/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.66 |
| ▸ | ALPG | P10696 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.62 |
| ▸ | METAP1 | P53582 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 10/20 | 0.59 |
| ▸ | MITF | O75030 | 8/20 | 0.59 |
| ▸ | PKM | P14618 | 6/20 | 0.59 |
| ▸ | GFER | P55789 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13024523 | 1.00 | F2 (1.00) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL1065724 | 1.00 | F2 (1.00) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL14712884 | 0.88 | F2 (0.78) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL3181280 | 0.81 | TDP1 (1.00) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL16542997 | 0.78 | DUSP3 (1.00) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL20156860 | 0.78 | F2 (0.63) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL3471124 | 0.77 | MEN1 (0.80) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL3471120 | 0.77 | MEN1 (0.80) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL14712984 | 0.77 | MEN1 (0.80) | F2TDP1MEN1KMT2ARECQL | |
| SCHEMBL8172539 | 0.77 | F2 (0.62) | F2TDP1MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| EP-2222326-B2 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | VIB VZW (BE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2222326-B1 | Inhibitors of MALT1-proteolytic activity and uses thereof | VIB VZW (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110021548-A1 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021548-A1 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F2 4188/4885TDP1 1427/4885MEN1 157/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4188/4885TDP1 1427/4885MEN1 157/4885 |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | F2 4684/4885TDP1 153/4885MEN1 2410/4885 |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAK1 | F2 4611/4885TDP1 289/4885MEN1 1885/4885 |
| US-20110021548-A1 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | MMEL1, CTRL, ZFR | F2 4498/4885TDP1 520/4885MEN1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.